scholarly journals Geographic variation in health insurance coverage : United States, 2019

2021 ◽  
Author(s):  
Robin A. Cohen ◽  
◽  
Emily P. Terlizzi ◽  
Amy E. Cha ◽  
Michael E. Martinez ◽  
...  
Keyword(s):  
Public Health ◽  
United States ◽  
Health Insurance ◽  
Geographic Variation ◽  
Private Health Insurance ◽  
Insurance Coverage ◽  
Health Insurance Coverage ◽  
Public Health Insurance ◽  
National Estimates ◽  
State Regional

This report presents state, regional, and national estimates of the percentage of persons who were uninsured, had private health insurance coverage, and had public health insurance coverage in 2019.

scholarly journals Geographic Variation in Health Insurance Coverage: United States, 2020

2022 ◽  
Author(s):  
Emily Terlizzi ◽  
Robin Cohen
Keyword(s):  
Public Health ◽  
United States ◽  
Health Insurance ◽  
Geographic Variation ◽  
Private Health Insurance ◽  
Insurance Coverage ◽  
Health Insurance Coverage ◽  
Public Health Insurance ◽  
National Estimates ◽  
State Regional

This report presents state, regional, and national estimates of the percentage of people who were uninsured, had private health insurance coverage, and had public health insurance coverage at the time of the interview.

scholarly journals The Public Health Insurance Coverage of Novel Targeted Anticancer Medicines in China—In Favor of Whom? A Retrospective Analysis of the Insurance Claim Data

2021 ◽  
Vol 12 ◽  
Author(s):  
Mingshuang Li ◽  
Yifan Diao ◽  
Jianchun Ye ◽  
Jing Sun ◽  
Yu Jiang
Keyword(s):  
Public Health ◽  
Lung Cancer ◽  
Health Insurance ◽  
Insurance Coverage ◽  
Health Insurance Coverage ◽  
Claim Data ◽  
Public Health Insurance ◽  
The Public ◽  
Supplementary Health Insurance ◽  
Insurance Claim Data

Objectives: This study took Fuzhou city as a case, described how the public health insurance coverage policy in 2016 of novel anti-lung cancer medicines benefited patients, and who benefited the most from the policy in China.Methods: This was a retrospective study based on health insurance claim data with a longitudinal analysis of the level and trend changes of the monthly number of patients to initiate treatment with the novel targeted anti-lung cancer medicines gefitinib and icotinib before and after health insurance coverage. The study also conducted a multivariate linear regression analysis to predict the potential determinants of the share of patient out-of-pocket (OOP) expenditure for lung cancer treatment with the study medicines.Results: The monthly number of the insured patients in Fuzhou who initiated the treatment with the studied novel targeted anti-lung cancer medication abruptly increased by 26 in the month of the health insurance coverage (95% CI: 14–37, p < 0.01) and kept at an increasing level afterward (p < 0.01). By controlling the other factors, the shares of OOP expenditure for lung cancer treatment of the patients who were formal employee program enrollees not entitled to government-funded supplementary health insurance coverage and resident program enrollees were 18.3% (95% CI: 14.1–22.6) and 26.7% (95% CI: 21.0–32.4) higher than that of the patients who were formal employee program enrollees with government-funded supplementary health insurance coverage.Conclusion: The public health insurance coverage of novel anti-lung cancer medicines benefited patients generally. To enable that patients benefit from this policy more equally and thoroughly, in order to achieve the policy goal of not to leave anyone behind, it is necessary to strengthen the benefits package of the resident program and to optimize the current financing mechanism of the public health insurance system.

Financing and Insurance

2018 ◽  
Author(s):  
Samuel H Zuvekas ◽  
Earle Buddy Lingle ◽  
Ardis Hanson ◽  
Bruce Lubotsky Levin
Keyword(s):  
Public Health ◽  
United States ◽  
Health Insurance ◽  
Insurance Coverage ◽  
Healthcare Providers ◽  
Health Insurance Coverage ◽  
Healthcare Services ◽  
Safety Net ◽  
The United States ◽  
Public And Private

The complexity of US healthcare systems is staggering. In 2015, Americans spent approximately $3.7 trillion on healthcare, averaging almost $10,000 per person. Further, Americans rely on a mixture of public and private health insurance coverage to pay for the bulk of the healthcare services they receive. To provide a better understanding of the financing of healthcare in the United States, this chapter examines major government healthcare programs and funding. It begins with a look at the US public health insurance system and the healthcare “safety net,” comprised of a patchwork of public, private, and philanthropic providers and programs. The next sections look at how US insurers and families pay doctors, hospitals, nursing homes, and other healthcare providers to deliver services in the United States and how pharmacy services are financed in public health.

scholarly journals Paying for Prevention: Challenges to Health Insurance Coverage for Biomedical HIV Prevention in the United States

2012 ◽  
Vol 38 (4) ◽  
pp. 607-666 ◽  
Author(s):  
Kristen Underhill
Keyword(s):  
Public Health ◽  
United States ◽  
Health Insurance ◽  
Hiv Prevention ◽  
Insurance Coverage ◽  
Health Insurance Coverage ◽  
The United States ◽  
Antiretroviral Drugs ◽  
Biomedical Hiv Prevention ◽  
Legal Grounds

Reducing the incidence of HIV infection continues to be a crucial public health priority in the United States, especially among populations at elevated risk such as men who have sex with men, transgender women, people who inject drugs, and racial and ethnic minority communities. Although most HIV prevention efforts to date have focused on changing risky behaviors, the past decade yielded efficacious new biomedical technologies designed to prevent infection, such as the prophylactic use of antiretroviral drugs and the first indications of an efficacious vaccine. Access to prevention technologies will be a significant part of the next decade's response to HIV, and advocates are mobilizing to achieve more widespread use of these interventions. These breakthroughs, however, arrive at a time of escalating healthcare costs; health insurance coverage therefore raises pressing new questions about priority-setting and the allocation of responsibility for public health. The goals of this Article are to identify legal challenges and potential solutions for expanding access to biomedical HIV prevention through health insurance coverage. This Article discusses the public policy implications of HIV prevention coverage decisions, assesses possible legal grounds on which insurers may initially deny coverage for these technologies, and evaluates the extent to which these denials may survive external and judicial review. Because several of these legal grounds may be persuasive, particularly denials on the basis of medical necessity, this Article also explores alternative strategies for financing biomedical HIV prevention efforts.

scholarly journals Estimating Premium Sensitivity for Children's Public Health Insurance Coverage: Selection but No Death Spiral

2014 ◽  
Vol 50 (2) ◽  
pp. 579-598 ◽  
Author(s):  
James Marton ◽  
Patricia G. Ketsche ◽  
Angela Snyder ◽  
E. Kathleen Adams ◽  
Mei Zhou
Keyword(s):  
Public Health ◽  
Health Insurance ◽  
Insurance Coverage ◽  
Health Insurance Coverage ◽  
Public Health Insurance ◽  
Death Spiral
Sign in / Sign up

Export Citation Format

Share Document